Home / Insights / FDA Watch brief
FDA Watch brief
Microbes still lead OTC recalls. Procedures still lead the 483s.
The October 2026 brief: what FDA recalled and what investigators wrote down over the last 12 months, and the one thing to do about it this month.
Founder, Claraxis Group · former FDA site contact and plant manager
Each month Claraxis pulls FDA recall and inspection data through FDA Watch and writes down what an operator should do about it. This edition covers the 12 months to October 11, 2026.
Microbes still lead OTC recalls
Microbial contamination is still the top reason OTC and personal care products get recalled: 21 of 57 recall events in the last 12 months (37%), more than twice the next cause. Three of those 57 were Class I, the category FDA reserves for products with a reasonable probability of serious harm.
Procedures still lead the Form 483s
These are the citations investigators wrote most often in drug and OTC plants over the same period.
| Rank | Citation | Observations |
|---|---|---|
| 1 | 21 CFR 211.22(d): quality unit procedures not in writing or not followed | 106 |
| 2 | 21 CFR 211.192: investigations of discrepancies and failures | 94 |
| 3 | 21 CFR 211.160(b): scientifically sound laboratory controls | 67 |
| 4 | 21 CFR 211.100(a): written production and process control procedures | 60 |
Form 483 observations in drug and OTC establishments, 12 months to October 11, 2026.
Water
Seven recalls in three years named water-borne organisms. The most recent OTC case was a Class I recall in January 2026 naming Achromobacter. Investigators wrote 14 observations on objectionable-microorganism controls in non-sterile drug plants (21 CFR 211.113(a)) and 31 on water systems. The USP purified water hub keeps the live list.
Outside OTC
In food, undeclared allergens caused 186 of 528 recall events (35%), and supplier verification under the Foreign Supplier Verification Program (21 CFR 1.502(a)) drew 325 observations. In medical devices, design, software or component issues caused 360 of 979 recall events (37%).
Operator’s read. Three of the top four drug citations are about procedures: missing, not followed, or investigations that stop at “operator error”. This month, walk your five most-used procedures with the people who run them and mark every step the floor does differently. That list is your inspection risk, ranked.
Data: Claraxis FDA Watch, built on openFDA enforcement reports and FDA inspection data, pulled October 11, 2026. Counts are recall events and Form 483 observations as published by FDA; one recall event can cover several products. See the live numbers →
“What set Kobe apart was technical rigor combined with sound judgment. He was the FDA point of contact for the pilot plant in Piscataway. He doesn’t stop at diagnosing a problem; he builds the system that keeps it fixed.”
Want a second set of eyes?
A 30-minute call, then a written scope before any commitment. Kobe replies personally within one business day.